De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and T
published in: Journal of Clinical Oncology
date of publication: 2017-07-06
language: English
main subject: Germany
Cites articles
There is nothing here
Article - wd:Q33443385